Leukocyte adhesion to kidney cells is an early event in renal inflammation, such as glomerulonephritis. We developed an experimental model of monocyte adhesion to cultured human mesangial cells. U-937 myelomonocytic leukaemia cells, similar to peripheral blood human monocytes, irreversibly bound to mesangial cell monolayers upon 30-180 min coincubations (to a max. of 13 600+/-1100/cm(2) monolayer), as assessed by cell counting, U-937 labelling with H-3-thymidine, and colorimetry of nuclear staining with crystal violet. Adhesion was enhanced in mesangial cells proliferating in response to 17% fetal bovine serum, indicating expression of a proinflammatory phenotype. E. coli lipopolysaccharide (LPS), tumour necrosis factor-alpha (TNF-alpha) and protein kinase C activation with phorbol myristate acetate (PMA) potentiated monocyte binding during either coincubation or 24-h pretreatment (0.1 mu M PMA, +200+/-21%). Binding was also promoted by pretreatment with vasoconstrictors, such as the thromboxane A(2) mimetic, U-46619 (10 nM-1 mu M, max. +35+/-3%), or 1 mu M angiotensin II (+61+/-4%). To elucidate the mechanisms of monocyte adhesion, we analysed the adhesion molecules expressed by human mesangial cells, employing reverse transcription/polymerase chain reaction to detect ICAM-1, VCAM-1 and E-selectin gene expression. Proliferating cells express VCAM-1 and ICAM-1, confirmed by immunocytochemical staining and 79+/-3% inhibition of stimulated adhesion by pretreatment of mesangial cells with an anti-ICAM-1 monoclonal Ab. E-selectin transcription was not detectable. VCAM-1, but not ICAM-1, mRNA content was increased by LPS and TNF-alpha, while immunostaining of fixed cells indicated stimulation of ICAM-1 and VCAM-1 protein by LPS, TNF-alpha. and, to a lesser extent, U-46619. Thus, post-transcriptional regulation of ICAM-1/VCAM-1 or expression of other adhesion molecules may account for vasoconstrictor-enhanced binding of monocytes to human mesangial cells. These findings underscore the importance of mesangial 'priming' by inflammatory or vasoactive mediators in leukocyte chemoattraction during glomerular disease.